18th Congress of the European Society for Organ Transplantation

24 - 27 September 2017
Barcelona, Spain

Transplantation
BigBangBarcelona

Advanced programme
Dear Colleagues, Dear Friends,

The 18th Congress of ESOT will take place in Barcelona, one of the most cosmopolitan and attractive cities of the South Europe and the Mediterranean area. The ESOT 2017 Congress will include most of the hot topics in modern transplant medicine like personalized medicine, big data in transplantation and challenges in innovation. Also relevant clinical and immunological topics on solid organ transplantation will be discussed. Finally, new technologies, and the race between repair or create new organs will be updated. All this exciting programme will be developed by the top experts coming worldwide.

Barcelona is the perfect host city; it interweaves tradition and avant-garde into a multi-layered identity, from the history-laden Gothic quarter to the 22@district, reaching out the future: from the masterpieces of local modernism to the statements of global architects; from Cuatre Gats, that guards culinary tradition, to chef Ferran Adrià’s cutting edge innovation lab; from the unique Catalan heritage to the diversity brought by multi-ethnicity; from the buzz of its markets to the vitality of its research centres and universities. Energy and passion are palpable anywhere: among those enamoured and inspired by the city are designers, artists, architects, entrepreneurs who have chosen it as a stage for their intricate creations or flocks of tourists marvelled by the city’s visual charms and romantic flair. Barcelona is a modern and sophisticated city with a very rich cultural life and has a broad offer of leisure opportunities to satisfy and delight delegates.

Both the Spanish and Catalan Transplantation Societies, together with the local scientific community, welcome you on board and look forward to seeing you in Barcelona!

Valentín Cuervas-Mons and Antonio Román

CONGRESS CHAIRS

Dear Colleagues, Dear Friends,

We would like to invite you to a new level of medical meetings in transplantation at the BigBangBarcelona conference. Transplantation has emerged from the decades of an early experimental procedure to an established first line therapy for organ failure. While mechanistic devices or fully artificial organs may be available in many decades from now, the fate of the patients suffering from organ failure today and in the next years, will depend on the progress we will achieve with transplantation.

The discrepancy between the high demand and the shortage in organs available remains a challenge. Amongst the many obstacles highlighted at the congress, progress in transplantation with organs from living donors but also advancements in normothermic perfusion and other seminal technologies will be addressed. Novel drugs, protocols for immunomodulation and tolerance but also surrogate endpoints for clinical trials in order to enhance the drug development remain critically important topics in the field. The BigBangBarcelona congress might help to refine our knowledge of basic science and clinical concepts to improve transplantation in a holistic approach.

At ESOT we have put a focus on the quality of the science but also the formats in which the content is delivered and the opportunity to network with your colleagues. The fully digital conference, the AllESOTApp, the Hybrid Meeting Concept are only few examples of how ESOT has modernized medical conferencing. In 2017, the technological enhancement of your conference experience will be nothing short of groundbreaking.

Barcelona was the venue of the ESOT congress in 1989 when ESOT was a young society that crystalized an emergent European transplant community with the eclosion of solid organ transplant programs after the introduction of cyclosporine. Today, Barcelona is a paradigm of a vibrant Mediterranean city, the home of Gaudi, the home of Las Ramblas and Lionel Messi’s right and left legs. Barcelona is home to modern art, home to spotless beaches, home to eternal nightlife, home to eminent romance and modern charm. Come on and join us at BigBangBarcelona.

Josep Maria Grinyó and Stefan Schneeberger

SCIENTIFIC PROGRAMME COMMITTEE CHAIRS
Top ten reasons to attend

1. Enjoy a stimulating, rejuvenated format with a focus on interaction and information exchange and the latest developments in the field of transplantation.

2. Be inspired, educated, connected and entertained.

3. Discuss with experts and innovative thinkers from all fields.

4. Understand the latest trends in biomarkers, biologicals and immunosuppression and how this may change patient care.

5. Learn about the latest discoveries in the science of transplantation and aging.

6. Experience translational research and recent developments at the interjunction between basic science and clinical care.

7. Attend sessions addressing the greatest surgical or immunological challenges.

8. Discuss present and upcoming challenges in transplantation: where business, legislation and medicine/science meet.

9. Present your work and be selected as a case/topic for focused discussions – guided and instructed by key opinion leaders in the field.

10. Get engaged in this interactive meeting and take an active role in shaping the future of transplantation research and medicine.

Index

Welcome to BigBangBarcelona 2
Top ten reasons to attend 3
Scientific programme overview 4
Congress Committees and ESOT Council 6

Scientific Programme

Specialty symposia and special sessions 8
Sunday 24 September 19
Monday 25 September 20
Tuesday 26 September 26
Wednesday 27 September 33

Transplant Education Campfire 36
Registration fees 37
ESOT awards 2017 38
ESOT partners and congress supporters 40
Corporate symposia 42
General information 43
**SUNDAY 24 SEPTEMBER**

8.30-9.00  Corporate Parallel Symposia
9.00-9.10  Organ donation. Meeting by EDTCO
9.10-9.30  The future of transplantation. Workshop by YPT
9.30-9.50  New challenges for a fair allocation by EPITA
9.50-10.10  Humoral alloimmunity. Joint symposium
10.10-10.30  Development, ageing and regeneration by BSC
10.30-10.50  Molecular diagnosis in thoracic tx by ECTTA
10.50-11.10  Beyond hand and face transplantation by VCA
11.10-11.30  Hot topics in living and deceased donation by ELPAT
11.30-11.45  Coffee break
11.45-12.05  Specialty Symposia
12.05-12.30  Bile ducts in liver and intestine by ELITA
12.30-12.45  Organ preservation and enhancements by LITA
12.45-13.00  Mix and match: the right organ for the right recipient by IMMUcor
13.00-13.15  The biomarker perspective: prime time or perpetual promise by ECTTA
13.15-13.30  Best Abstract Challenge
13.30-13.45  The Devil’s Advocate Basic science
13.45-14.00  From Learners to Leaders Campfire
14.00-14.15  Plenary 1
14.15-14.30  Big Bang in Transplantation
14.30-14.45  Coffee break
14.45-15.00  Big Bang 2 Value and costs
15.00-15.15  Big Bang 1 Technology enhanced medicine
15.15-15.30  Future leaders on stage: life changing stories
15.30-15.45  Elevator Pitch
15.45-16.00  Brief Orals
16.00-16.15  Full Orals
16.15-16.30  Coffee break
16.30-16.45  Big Bang 2 Value and costs
16.45-17.00  Big Bang 1 Technology enhanced medicine
17.00-17.15  Future leaders on stage: life changing stories
17.15-17.30  Elevator Pitch
17.30-17.45  Brief Orals
17.45-18.00  Full Orals
18.00-18.15  Plenary 2
18.15-18.30  Trials and Tribulation in Transplantation
18.30-18.45  Break
18.45-19.00  Elevator Pitch
19.00-19.15  Brief Orals
19.15-19.30  Full Orals
19.30- Networking Cocktail

**MONDAY 25 SEPTEMBER**

7.30  Educational Track
8.00  Histo-compatibility: your worst nightmare?
8.30  Live donation
9.00  Full Orals
9.10  Mix and match: the right organ for the right recipient
9.30  The biomarker perspective: prime time or perpetual promise
10.00  Coffee break
11.10  Best Abstract Challenge
11.30  Full Orals
13.00  Corporate Parallel Lunch Symposia *
13.15  Future leaders on stage: life changing stories
13.30  Elevator Pitch
13.45  Brief Orals
14.00  Plenary 2
14.15  Trials and Tribulation in Transplantation
14.30  Coffee break
16.00  Big Bang 2 Value and costs
16.15  Big Bang 1 Technology enhanced medicine
16.30  Future leaders on stage: life changing stories
16.45  Elevator Pitch
17.00  Brief Orals
17.15  Full Orals
18.00  Corporate Plenary Symposium
18.15  Astellas
19.00  Networking Cocktail

* Chiesi, One Lambda, Sandoz
The target audience for this conference includes all fields in healthcare and research with an affiliation in transplantation. This includes but is not limited to:

- Transplant surgeons.
- Physicians of all fields with an involvement in transplantation.
- Psychologists, coordinators, nurses.
- General surgeons and clinicians with an interest in transplantation.
- Transplant sciences.
- Nutrition and rehabilitation specialists and coordinators.
- Transplant pharmacists.

Further, healthcare professionals with an involvement in treatment of organ failure, cell therapy, tissue and regenerative medicine are warmly welcome to our conference.
# ESOT 2017 Congress Committee

**CONGRESS CHAIRS**

Valentín Cuervas-Mons, Madrid, Spain  
Antonio Román, Barcelona, Spain

**EXECUTIVE ORGANISING COMMITTEE**

Josep Maria Grinyó, Barcelona, Spain  
Stefan Schneeberger, Innsbruck, Austria  
Maarten Naesens, Leuven, Belgium  
Gabriel Oniscu, Edinburgh, United Kingdom  
Olivier Thaunat, Lyon, France  
Annalisa Ponchia, ESOT CEO

---

# ESOT 2017 Scientific Program Committee

**CHAIRS**

Josep Maria Grinyó, Barcelona, Spain  
Stefan Schneeberger, Innsbruck, Austria

**MEMBERS**

Marina Berenguer, Valencia, Spain  
Oriol Bestard, Barcelona, Spain  
Georg Böhmg, Vienna, Austria  
Pietro Cippà, Zurich, Switzerland  
Frans Claas, Leiden, The Netherlands  
Valentín Cuervas-Mons, Madrid, Spain  
Eelco de Koning, Leiden, The Netherlands  
Marc Dahlke, Regensburg, Germany  
Frank Dor, London, United Kingdom  
Alexandre Loupy, Paris, France  
Lorna Marson, Edinburgh, United Kingdom  
Nicolas Müller, Zurich, Switzerland  
Maarten Naesens, Leuven, Belgium  
Arne Neyrinck, Leuven, Belgium  
Gabriel Oniscu, Edinburgh, United Kingdom  
Jacques Pirenne, Leuven, Belgium  
Antonio Román, Barcelona, Spain  
Hendrik Tevaearai, Bern, Switzerland  
Olivier Thaunat, Lyon, France

---

# ESOT 2017 Local Committee

**CHAIR**

Josep Maria Grinyó, Nephrology, Barcelona

**MEMBERS**

Gonzalo Crespo, Hepatology, Barcelona  
María G. Crespo Leiro, Cardiology, La Coruña  
José Mª Cruzado, Nephrology, Barcelona  
Valentín Cuervas-Mons, Hepatology, Madrid  
(President of the Spanish Transplantation Society)  
Alex Gutiérrez-Dalmau, Nephrology, Zaragoza  
Beatriz Domínguez-Gil, Nephrology, Madrid  
Domingo Hernández Marrero, Nephrology, Málaga  
Laura Lladó, Hepatology, Surgery, Barcelona  
Rafael López Andújar, Nephrology, Valencia  
Marcos López-Hoyos, Immunology, Santander  
Nuria Masnou, Organ Procurement, Intensive Care, Girona  
Sonia Mirabet, Cardiology, Barcelona  
Francisco Moreso, Nephrology, Barcelona  
Eduard Palou, Immunology, Barcelona  
Antonio Román, Pulmonology, Barcelona  
(President of the Catalan Transplantation Society)  
Daniel Serón, Nephrology, Barcelona
ESOT 2017 Sponsorship Advisory Committee

MEMBERS
John Forsythe, Edinburgh, United Kingdom
Thierry Berney, Geneva, Switzerland
Stefan Schneeberger, Innsbruck, Austria
Vassilios Papalois, London, United Kingdom
Annalisa Ponchia, ESOT CEO

ESOT 2016-2017 Council

PRESIDENT
Thierry Berney, Geneva, Switzerland

PRESIDENT ELECT
Stefan Schneeberger, Innsbruck, Austria

SECRETARY
Vassilios Papalois, London, United Kingdom

COUNCILLORS
Diego Cantarovich, Nantes, France
Franco Citterio, Rome, Italy
Marc Dahlke, Regensburg, Germany
Luuk Hilbrands, Nijmegen, The Netherlands
Maarten Naesens, Leuven, Belgium
Björn Nashan, Hamburg, Germany
Birgit Sawitzki, Berlin, Germany
Gabriel Oniscu, Edinburgh, United Kingdom
Olivier Thaunat, Lyon, France

PAST PRESIDENT
John Forsythe, Edinburgh, United Kingdom

TREASURER
Luciano Potena, Bologna, Italy

MEMBERS
Gerald Brandacher, Baltimore, United States
VCA Chair
Julien Charpentier, Paris, France
EDTCO Chair
Frank Dor, London, United Kingdom
EC Chair
Christophe Duvoux, Paris, France
ELITA Chair
Henri Leuvenink, Groningen, The Netherlands
BSC Chair
Emma Massey, Rotterdam, The Netherlands
ELPAT Chair
Arne Neyrinck, Leuven, Belgium
ECTTA Chair
Rainer Oberbauer, Vienna, Austria
EKITA Chair
Liset Pengel, London, United Kingdom
CET
Johann Pratschke, Berlin, Germany
EPITA Chair
Francesca Tinti, Rome, Italy
YPT Chair
Marjo Van Helden, Nijmegen, The Netherlands
ETAHP Chair
**SPECIALTY UPDATE SYMPOSIUM ELITA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 12.50</td>
<td>09.00 – 10.40</td>
<td>Bile ducts in liver transplantation - do we make progress?</td>
<td>Luca Belli, Milan, Italy, Wojciech Polak, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Session 1</strong></td>
<td></td>
</tr>
<tr>
<td>09.15</td>
<td></td>
<td>Introduction</td>
<td>Christophe Duvoux, Paris, France and Gabriela Berlakovich, Vienna, Austria</td>
</tr>
<tr>
<td>09.35</td>
<td></td>
<td>Classification, epidemiology and pathophysiology of biliary complications after liver transplantation</td>
<td>Silvio Nadalin, Tübingen, Germany</td>
</tr>
<tr>
<td>09.55</td>
<td></td>
<td>How to treat the biliary tract during liver procurement and during transplantation?</td>
<td>Nicolas Meurisse, Liège, Belgium</td>
</tr>
<tr>
<td>10.40 – 11.00</td>
<td></td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11.00 – 12.50</td>
<td>11.00 – 12.00</td>
<td>Session 2</td>
<td></td>
</tr>
<tr>
<td>11.10</td>
<td></td>
<td>Non-anastomotic strictures in DCD liver transplantation – how to prevent them?</td>
<td>Robert Porte, Groningen, The Netherlands</td>
</tr>
<tr>
<td>11.30</td>
<td></td>
<td>How far can we go with conservative management of biliary complications after liver transplantation?</td>
<td>Herold Metselaar, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>11.50</td>
<td></td>
<td>Good functioning graft with severe biliary complications - when is the right time for re-transplantation?</td>
<td>Darius Mirza, Birmingham, United Kingdom</td>
</tr>
<tr>
<td>12.10</td>
<td></td>
<td>How the pathologist can help clinician in decision making in case of biliary complications?</td>
<td>Desley Neil, Birmingham, United Kingdom</td>
</tr>
</tbody>
</table>

**OBJECTIVES**  
To provide the liver transplant professionals with up to date information on donor selection, anatomical and surgical technical pitfalls and management of recipients after small for size syndrome in split and living donor liver transplants.

**TARGET AUDIENCE**  
Liver transplant surgeons and hepatologists, HPB surgeons and general hepatologists, HPB oncologists, specialist nurses in liver transplantation, HPB, hepatology and oncology.

---

**The European Liver and Intestine Transplantation Association** is a multi-disciplinary Society of health professionals in liver and intestine transplantation which is the official professional society delegated by ESOT for liver and intestine transplantation in Europe.

**GOALS**  
To provide a range of educational activities, stimulate discussion and influence European legislation in liver and intestine transplantation. To stimulate clinical research and publications from analysis of the registry, in partnership with the European Liver Transplant Registry.

**AIMS**  
Our aim is to set guidelines and standards and to provide education and support in liver and intestine transplantation within the European Countries.
**New challenges: fair allocation (recipient) and donation (donor)**

**Session 1. New challenges for a fair allocation (recipient)**

**CHAIRS:** Helmut Arbogast, Munich, Germany  
Steve White, Newcastle, United Kingdom

**09.00** Challenges in different countries. Eurotransplant is in there with the other countries  
Eelco de Koning, Leiden, The Netherlands

**09.10** Experiences with a common waiting list for islets Tx in the United Kingdom  
James Shaw, Newcastle, United Kingdom

**09.25** New allocation system: the Swiss solution  
Roger Lehmann, Zurich, Switzerland

**09.35** What about France?  
Marie-Alice Macher, France

**09.50** Pancreas allocation in North Italy Transplant program (NITp)  
Massimo Cardillo, Milan, Italy

**10.15** The first pancreas transplants were performed 50 years ago. One of the surgeons recalls how it happened and some consequences  
Frederick Merkel, Chicago, United States

**10.40 – 11.10** Break

**Session 2. New challenges in donation (donor)**

**CHAIRS:** Lorenzo Piemonti, Milan, Italy  
Johann Pratschke, Berlin, Germany

**11.10** What is the crucial information for accepting an organ? Are scoring systems helpful?  
Raja Kandaswamy, Minneapolis, United States

**11.40** Update on marginal donor utilization  
Peter Friend, Oxford, United Kingdom

**12.10** Decreasing numbers for beta-cell replacement: what is the reason?  
Antonio Secchi, Milan, Italy

**OBJECTIVES**  
To review recent developments in pancreas and islet transplantation.

**TARGET AUDIENCE**  
Transplant surgeons and physicians, transplant coordinator, nurses and medical student with an interest in transplantation of pancreas and islets.
**SPECIALTY UPDATE SYMPOSIUM**

**EKITA & ERA-EDTA DESCARTES**

**Joint Symposium. Humoral alloimmunity**

**09.00 – 12.20**

**Session 1**

**CHAIRS:** Fritz Diekmann, Barcelona, Spain
Ondrej Viklicky, Prague, Czech Republic

09.00 **Basics of the HLA system**
Caner Süsal, Heidelberg, Germany

09.20 **External validity and variability of solid phase results**
Markus Wahrmann, Vienna, Austria

09.40 **HLA single epitope matching becomes real?**
Frans Claas, Leiden, The Netherlands

10.00 **Preformed HLA DSAs and outcomes**
Christophe Legendre, Paris, France

10.20 **De novo HLA-DSAs and hard outcomes. How to determine risk (class, number, complement activation?)**
Hans J. W. de Fijter, Leiden, The Netherlands

10.40 – 11.00 **Break**

11.00 – 12.20 **Session 2**

**CHAIRS:** Fritz Diekmann, Barcelona, Spain
Ondrej Viklicky, Prague, Czech Republic

11.00 **Alloimmunity trough non-HLA, the human knock out experiment**
Rainer Oberbauer, Vienna, Austria

11.20 **Complement blockade and outcomes – novel approaches beyond eculizumab**
Georg Böhmig, Vienna, Austria

11.40 **Treatment of ABMR features in management biopsies**
Ondrej Viklicky, Prague, Czech Republic

12.00 **Underlying mechanisms of spontaneous operational tolerance**
Annick Massart, Brussels, Belgium

**OBJECTIVES** | To provide an overview and offer specific solutions for the ‘complicated’/sensitized patient. Solutions range from individualization through omics technologies to bioinformatics approaches.

**TARGET AUDIENCE** | Transplant surgeons and physicians, nephrologist, immunologists at all stages of training and expertise.

**EKITA** is the kidney section of ESOT and deals with all aspects of renal transplantation. As a European platform, EKITA supports research, education and clinical work in this area. Furthermore, EKITA is highly ambitious in preparing policies and creating transnational interactions to advance renal allografting in all European member states.

**GOALS** | The main goal of EKITA is to improve quality of life of people with ESRD by advancing all aspects of kidney transplantation.

**AIMS** | The ultimate aim of EKITA is the optimization of transplantation trough activities in research, education, clinical collaboration and health policy.
**SPECIALTY UPDATE SYMPOSIUM BSC**

**Development, ageing and regeneration**

**BSC Session**

**CHAIRS:** Henri Leuvenink, Groningen, The Netherlands
Nina Pinat-Michalek, Vienna, Austria

09.00 **Organogenesis and development of organs C18**
Stephen A. Duncan, Charleston, United States

09.45 **Ageing donor organs and recipients’ immune systems**
Michiel Betjes, Rotterdam, The Netherlands

10.30 **Generation of kidney tissue from iPS**
Minoru Takasato, Kobe, Japan

**OBJECTIVES**
To give in-depth insight in biological processes related to ageing. To provide general insight in organ development and regeneration. To implement general knowledge of ageing and regeneration in the transplantation field.

**TARGET AUDIENCE**
Basic scientists, transplant immunologists, regenerative medicine researchers, transplant physicians.

11.10 – 12.50 **Joint BSC and VCA Session**

**CHAIRS:** Gerald Brandacher, Baltimore, United States
Nina Pilat-Michalek, Vienna, Austria

11.10 **VCA and regenerative medicine: a perfect couple?**
Gerald Brandacher, Baltimore, United States

11.20 **Creating stem cell niches in vitro**
Martin J. Hoogduijn, Rotterdam, The Netherlands

11.50 **Engineering functional tissues: The Holy Grail or an attainable goal?**
Tahera Ansari, Harrow, United Kingdom

12.20 **Pediatric reconstructive transplantation**
Lawrence Levin, Philadelphia, United States

The Basic Science Committee promotes Basic Science in transplantation in Europe.

**GOALS**
Translation of innovation into clinical activity.
Communication between basic scientists and clinicians.
Collaboration between laboratories in Europe.
**SPECIALTY UPDATE SYMPOSIUM VCA**

**09.00 – 12.50**

**Beyond hand and face transplantation**

**VCA Session**

**CHAIRS:** Gerald Brandacher, Baltimore, United States
             Fadi Issa, Oxford, United Kingdom

09.00

**Uterus transplantation: current status and future directions**
Mats Brannstrom, Göteborg, Sweden

09.30

**Penis transplantation: a viable option to restore form and function**
Frank Graewe, Stellenbosch, South Africa

10.00

**Regenerative medicine and VCA - competitors or perfect couple?**
Liam Grover, Birmingham, United Kingdom

10.30

**Novel technologies for local skin-specific drug delivery**
Constantin Coussios, Oxford, United Kingdom

**OBJECTIVES**
To discuss the latest developments and new indications in VCA. Discuss new strategies of cell-based immune modulation for VCA. Highlight how cutting edge technologies from tissue engineering and regenerative medicine can help advance the field of VCA.

**TARGET AUDIENCE**
Surgeons, physicians, researchers, transplant coordinators.

11.10 –12.50

**Joint BSC and VCA Session**

**CHAIRS:** Gerald Brandacher, Baltimore, United States
            Nina Pilat-Michalek, Vienna, Austria

11.10

**VCA and regenerative medicine: a perfect couple?**
Gerald Brandacher, Baltimore, United States

11.20

**Creating stem cell niches in vitro**
Martin J. Hoogduijn, Rotterdam, The Netherlands

11.50

**Engineering functional tissues: The Holy Grail or an attainable goal?**
Tahera Ansari, Harrow, United Kingdom

12.20

**Pediatric reconstructive transplantation**
Lawrence Levin, Philadelphia, United States

VCA has opened a new chapter in the field of transplantation, reconstructive and restorative surgery. This committee brings together 8 representatives of major European teams at the forefront in this field.

**GOALS**
Our goal is to raise the scientific and clinical development of Vascularized Composite Allotransplantation (VCA) in Europe and to serve as a platform for scientists and clinicians for information and exchange.
SPECIALTY UPDATE SYMPOSIUM | ELPAT

09.00 – 12.50
Hot topics in living and deceased donation

09.00 – 10.30
Session 1

CHAIRS: Annette Lennerling, Göteborg, Sweden
Willem Weimar, Rotterdam, The Netherlands

09.00
Children as deceased donors
Marion Siebelink, Groningen, The Netherlands

09.30
How and why should we perform psychological screening of living donors
Emma Massey, Rotterdam, The Netherlands

10.00
Pushing for more anonymous (unspecified) living kidney donations?
Christopher Burns-Cox, London, United Kingdom

10.30 – 11.00
Break

11.00 – 12.50
Session 2

CHAIRS: Annette Lennerling, Göteborg, Sweden
Willem Weimar, Rotterdam, The Netherlands

11.00
Is promotion of altruistic living donation killing altruism of the deceased?
Leonardo de Castro, Singapore, Republic of Singapore

11.30
Questioning the definitions of death
Michael Nair-Collins, Tallahassee, United States

12.00
Opportunities and hurdles in research in deceased donation
Rutger Ploeg, Oxford, United Kingdom

OBJECTIVES | To increase the knowledge, understanding, and skills to implement a successful living kidney exchange program.

TARGET AUDIENCE | Nephrologists, surgeons, psychologists, social workers, transplant coordinators, nurse practitioners.

Ethical, Legal, and Psychosocial Aspects of Organ Transplantation (ELPAT) is a European platform that brings continuity and progress in European research and dialogue on ethical, legal and psychosocial aspects of organ donation and transplantation.

GOALS | Provides a forum for discussion about ethical, legal, and psychosocial problems and questions related to donation and transplantation; Organizes regular, international open and invitational conferences.
The Thoracic Committee has been endorsed to promote initiatives aimed at improving the educational and scientific opportunities ESOT can offer to professionals involved in heart and lung transplantation.

**GOALS**
Our ambition is to become a gathering home to foster scientific growth, exchange programs, collaborative projects and funding opportunities dedicated to European heart and lung transplantation programs.

**AIMS**
Improve quality of care for patients with end-stage heart or lung disease and for thoracic organ transplant recipients. Advance education and stimulate networking amongst thoracic transplant professionals.

---

**SPECIALTY UPDATE SYMPOSIUM  ECTTA**

**09.00 – 12.50**

**Molecular diagnostics in thoracic transplantation**

**Session 1. Joint Session ECTTA-ERS**
To provide insights in key features of lung transplantation

**CHAIRS:** Arne Neyrinck, Leuven, Belgium
Robin Vos, Leuven, Belgium

09.00
How to personalise CLAD management
Robin Vos, Leuven, Belgium

09.20
Can LAS survive in Europe?
Jens Gottlieb, Hannover, Germany

09.40
Should we move from ventilation to awake ECMO?
Alexis Slama, Vienna, Austria

10.00
Is EVLP a tool for immunoregulation?
James Fildes, Manchester, United Kingdom

10.20
How extended is my donor?
Christian Benden, Zurich, Switzerland

10.40 – 11.00
Break

**Session 2. Joint Session ECTTA-ESC**
Advanced heart failure - when drugs alone are not enough: a case-based approach

**CHAIRS:** Sharon Hunt, Palo Alto, United States
Luciano Potena, Bologna, Italy

11.00
The patient sliding on inotropes
Andreas Zuckermann, Vienna, Austria

11.20
Right ventricular failure: LVAD, temporary RVAD or BiVAD?
Arjang Ruhparwar, Heidelberg, Germany

11.40
When to refer a patient for heart transplant or LVAD: a stepwise approach
Kristjan Karason, Göteborg, Sweden

12.00
Palliation and end of life care in end-stage heart failure
James Beattie, London, United Kingdom

**OBJECTIVES**
To provide updates on the etiologies, mechanisms, treatment strategies and diagnostic tools of early and late dysfunction of the transplanted heart and lungs. The lectures will focus on the main strategies and mechanisms leading to graft dysfunction starting from donor and organ management, to prevention of long-term chronic immunological injury leading to graft impairment.

**TARGET AUDIENCE**
Cardiologists, pneumologists, cardio-thoracic surgeons, anesthesiologists, transplant coordinators.
SPECIALTY UPDATE SYMPOSIUM  ETAHP

08.30 – 12.50
Healthy ageing after transplantation: sex, drugs and rock’n’roll
CHAIRS: Fabienne Dobbels, Leuven, Belgium
Ignacio Revuelta, Barcelona, Spain

08.40 – 10.00  Session 1. Let’s talk about sex
08.40  Sexuality after organ transplantation: shuffling between fears and dreams?
Paul Enzlin, Leuven, Belgium
09.10  Transplant drugs and pregnancy - contraception, pregnancy and breastfeeding
Helene Thomas, Bristol, United Kingdom
09.40  Interactive case discussion. So you want to have a baby: now what?
Andrea Devaney, Oxford, United Kingdom

10.00 – 10.50  Session 2. Cognitive functioning
10.00  Cognitive functioning pre- and post-transplant: eternal sunshine of the spotless mind?
Patrick Smith, Durham, United States
10.30  Interactive case discussion on cognitive functioning. 2 cases with long term perspective:
1. Deliberative non adherence due to cognitive deficit in a liver transplant recipient
Anna Forsberg, Lund, Sweden
2. Cognitive deficit after lung transplantation - a long-term perspective on consequences for self-management
Marion Wessels-Bakker, Utrecht, The Netherlands

11.10 – 12.50  Session 3. Frailty
11.10  The good, the bad and the frailty: new organs in rickety vehicles?
Edwin Van Adrichem, Groningen, The Netherlands
11.40  Optimal nutritional intervention in frailty: more than eating steak!
Francis Hollander, Utrecht, The Netherlands
12.10  Interactive case discussion. Frailty: not only a problem for the older patient - 2 cases
Marjo Van Helden, Nijmegen, The Netherlands

OBJECTIVES | The lectures will focus on post transplant lifestyle problems, the role of nurses and allied health professionals in promoting a healthy lifestyle, and non-medical interventions aiming to improve post-transplant self-management.

TARGET AUDIENCE | Nurses, physical therapists, dieticians, social workers, occupational therapists psychologists, among other allied healthcare professionals.

ETAHP reaches out to nurses (e.g. clinical nurses, advanced practice nurses and nurse coordinators (recipient care), psychologists, physical therapists, occupational therapists, social workers, dieticians, pharmacists and other disciplines working in the field of transplantation.

GOALS | Within ETAHP, nurses and allied healthcare professionals throughout Europe will be united to ensure the best care possible to all transplant patients, with the aim to optimize patient outcomes.

AIMS | We will do so by creating a strong European interdisciplinary platform to: share evidence based knowledge; exchange experiences and provide training; facilitate research and clinical collaborations; set the standards for the quality of care in transplant nursing and for allied health professionals.
ORGAN DONATION BY EDTCO

09.00 – 14.30 The next industrial revolution: new role for the transplant coordinator in organ recovery and repair

09.00 – 09.10 Welcome

09.10 – 10.40 Industry 4.0: New role for the transplant coordinator in organ recovery and repair

CHAIRS: David Paredes, Barcelona, Spain
        Dirk Ysebaert, Antwerp, Belgium

09.10 Heart donation in DCD donors: an option for other countries?
Stephen Large, Cambridge, United Kingdom

09.30 Ex situ organ perfusion: what are the benefits and the risks for organ repairing?
Diethard Monbaliu, Leuven, Belgium

09.50 New role and responsibilities: transplant technicians in organ preservation (in situ/ex situ)
Leonie Venema, The Netherlands

10.10 Discussion with the experts

10.40 – 10.55 Break

10.55 – 12.30 Donation revolution: changing paradigms

CHAIRS: Julien Charpentier, Paris, France
        Carl-Ludwig Fischer Froehlich, Frankfurt, Germany

10.55 Changes in cerebro-cardiovascular treatment incorporating donation as part of end of life care
Beatriz Dominguez-Gil, Madrid, Spain

11.15 Increase of patients in therapeutic ECMO, does it interfere in organ donation?
Régis Bronchard, Malakoff, France

11.35 Matching expanded donor profiles to selected recipients: HIV to HIV, successfully treated HCV to naive recipients?
Paolo Grossi, Varese, Italy

11.55 Discussion with the experts

12.30 – 14.30 Lunch symposium. Living donation: the redefined role of transplant coordinator?

CHAIRS: Nichon Jansen, Leiden, The Netherlands
        Sandor Mihaly, Budapest, Hungary

12.30 Pros and cons of transplant coordinators as donor advocate
Lisa Burnapp, London, United Kingdom

12.50 It’s time for financial incentives to promote living donation?
Medard Hilhorst, Rotterdam, The Netherlands

13.15 New challenges in living donation: Europe confronting transplant tourism and organ trafficking
Marta Lopez Fraga, Strasbourg, Germany

13.40 Paired kidney exchange between European countries to improve transplant opportunities
Bernadette J.J.M. Haase-Kromwijk, Leiden, The Netherlands

14.05 Discussion with the experts and closing remarks

OBJECTIVES | To promote better understanding of the barriers to deceased donation.
To develop knowledge and skills in end of life care, donor management and family support.
To enhance collaboration between healthcare professionals working in the fields of intensive care medicine and organ and tissue donation.

TARGET AUDIENCE | Healthcare professionals involved in intensive care and emergency medicine, end of life care, organ and tissue donation and coordination. Patient, family and society representatives, EU commissioners and political representatives.
WORKSHOP BY YPT

09.00 – 12.00

The transplant team: all for one - one for all

The ESOT YPT Workshop and its Presidential Debate gives you a chance to engage with a variety of speakers in a lively ‘town hall’ format, as well as connecting with other young transplant professionals from around the world.

The session will begin with talks from three key presenters on the past, present, and future of transplantation and open Q&As with each presenter. The second part sees sets of two speakers take contradicting viewpoints on several of the key issues facing young transplant professionals and tackling questions from the moderator and the audience.

Creators: Francesca Tinti, Roma, Italy
Mohammed Zeeshan Akhtar, Oxford, United Kingdom

09.00 – 10.35

Part I. The future of transplantation: 3 lectures on past, present and future

Chairs: Alice Koenig, Lyon, France
Thomas Resch, Innsbruck, Austria

09.05

The future of transplantation - historical perspective
Sir Roy Calne, Cambridge, United Kingdom

09.25

Open Q&A with Roy Calne

09.35

The future of transplantation - present perspective
Jan Lerut, Brussels, Belgium

09.55

Open Q&A with Jan Lerut

10.05

The future of transplantation - future perspective
Igor Sauer, Berlin, Germany

10.25

Open Q&A with Igor Sauer

10.35 – 10.50

Coffee break

10.50 – 12.00

Part II. Presidential debate

‘Town Hall’ format. Moderated discussion group in which a large audience is invited. The audience is composed of participants and a small number of spokespersons, who will address questions to the 2 speakers. A decided number of questions will come from the audience, while others will be posed by the moderator. The moderator will choose from a list of questions prepared before the event.

The theme: Career development in Europe - personal experience

Chair: John Forsythe, Edinburgh, United Kingdom

10.50

Introduction

10.55

Segment 1. The bittersweet life of a transplant trainee: ‘I can’t get no …’
Undine A. Gerlach-Runge, Berlin, Germany
Olivier Aubert, Paris, France

11.15

Segment 2. The importance of pre- and post-transplant care: ‘Love your -ologist’
Georgios Vrakas, Oxford, United Kingdom
Laure Elkrief, Geneva, Switzerland

11.35

Segment 3. The importance of research and publication: ‘You’re only as good as your impact factor’
Liset Pengel, London, United Kingdom
Simon Knight, Oxford, United Kingdom

11.55

Closing remarks and invitation to the Young Professional Journey at ESOT2017
John Forsythe, Edinburgh, United Kingdom

Objectives: Provide insights and promote debate on education and career development for young professionals in transplant. The workshop is divided into three parts focussing on different aspects around a common theme on education and career development.
SPECIAL SESSION

11.20 – 14.30

The coolest clinical trials in transplantation sponsored by the EU

Since the beginning of transplantation, clinical trials entertained in Europe contributed to the advancement of this exciting field. Not only large multicenter studies executed by pharmaceutical companies but also investigator-driven research is strongly present in Europe and contributing to the advancement of our field. Under the umbrella of the FP7 and HORIZON2020 frameworks of the European Commission, the EU is sponsoring large international research networks, also in transplantation. In this session, we listen to the stories of the protagonists in the EU-sponsored projects in the field of solid organ transplantation, and discuss the opportunities and hurdles encountered by these large international collaborative networks.

CHAIRS: Pierre Marquet, Limoges, France
Maarten Naesens, Leuven, Belgium

11.30
EU-funding of innovative approaches to solid organ transplantation
Jürgen Sautter, European Commission, Brussels, Belgium

11.50
ONE - A unified approach to evaluating cellular immunotherapy in solid organ transplantation
Edward K. Geissler, Regensburg, Germany

12.10
Bio-DrIM - Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation
Petra Reinke, Berlin, Germany

12.30 – 13.10
Lunch break

13.10
EUROSTAM - A Europe-wide strategy to enhance transplantation of highly sensitized patients on basis of acceptable HLA mismatches
Frans Claas, Leiden, The Netherlands

13.30
BIOMARGIN - Biomarkers of renal graft injury
Pierre Marquet, Limoges, France

13.50
COPE - Consortium for organ preservation in Europe: latest news
Rutger Ploeg, Oxford, United Kingdom

14.10 – 14.30
Q&A. Questions from the audience and discussion about opportunities for joint activities and important topics for the future of organ transplantation
### Sunday 24 September

#### PLENARY SESSION 1

**Big Bang in Transplantation**

The session will take you on a journey from the origins of transplantation to the present day. Recent advances in science open the gate to extending human life, defying nature. However, we are also learning from nature as to how to extend the life of organs and the entire human body. On the brink of the biggest adventure of the human race, stepping on a different planet, we face questions about the very essence of humanity.

**CREATED BY:** Maarten Naesens, Leuven, Belgium  
Gabriel Oniscu, Edinburgh, United Kingdom

**CHAIRS:** Josep Maria Grinyó, Barcelona, Spain  
Vassilios Papalois, London, United Kingdom

- **15.00** **Welcome address** by the Congress Chairs  
Valentín Cuervas-Mons, Madrid, Spain and Antonio Román, Barcelona, Spain

- **15.15** **ESOT presents: a story never before told!**

- **15.30** **A patient experience and viewpoint**  
Carole Lamarque, Antwerp, Belgium

- **16.00** **Hibernation and preservation**  
Robert H. Henning, Groningen, The Netherlands

- **16.20** **A glimpse into the on-going / near future of transplantation**  
Gerald Brandacher, Baltimore, United States

- **16.45** **KEYNOTE The human fate from a universal perspective - the race to Mars**  
John Bradford, Atlanta, United States

**17.45 – 18.45** Transplant International behind the scenes: ten ways to get your paper (not) rejected

This session will provide insight into how the decision is made whether a submitted paper gets accepted or rejected. To inform about parts of the decision process that are usually not visible to the author. To show examples of pitfalls to avoid when submitting a paper. To provide suggestions how to optimize your chances of acceptance.

**CHAIRS:** Rainer Oberbauer, Vienna, Austria  
Thomas Wekerle, Vienna, Austria

- **17.45** **Introduction**  
Rainer Oberbauer, Vienna, Austria and Thomas Wekerle, Vienna, Austria

- **17.55** **The editor’s perspective: do’s**  
Rainer Oberbauer, Vienna, Austria

- **18.15** **The editor’s perspective: don’t’s**  
Thomas Wekerle, Vienna, Austria

- **18.35** **Interactive discussion with the audience**

**17.45 – 18.45** e-Poster opening

**17.45 – 18.45** Elevator Pitch sessions

**17.45 – 18.45** Brief oral sessions
**Monday 25 September**

**EDUCATIONAL TRACK SESSION 1**

**Histocompatibility: your worst nightmare?**

**CHAIR:** Frans Claas, Leiden, The Netherlands  
David Taube, London, United Kingdom

07.30 – 09.00

**Application of Luminex® assays before and after transplantation**  
Christophe Legendre, Paris, France

07.45

**From actual towards virtual crossmatch**  
Craig Taylor, Cambridge, United Kingdom

08.00

**HLA epitope matching**  
Sebastiaan Heidt, Leiden, The Netherlands

08.15

**Hidden sensitization: the memory B cell repertoire**  
Oriol Bestard, Barcelona, Spain

08.30

**EDUCATIONAL TRACK SESSION 2**

**Live donation**

**CHAIRS:** Paolo Muiesan, Birmingham, United Kingdom  
Raj Thuraisingham, London, United Kingdom

07.30 – 09.00

**Laparoscopy replacing open surgery in live liver donation**  
Ki Hun Kim, Seoul, South Korea

07.45

**Governance and near miss events in live liver donation**  
Juan Carlos García-Valdecasas, Barcelona, Spain

08.00

**Minor clinical abnormalities in kidney donors**  
Rachel Hilton, London, United Kingdom

08.15

**Teaching minimally-invasive live donor nephrectomy**  
Lloyd Ratner, New York, United States

08.30

**08.00 – 09.00 Full oral sessions**

**08.00 – 09.00 Brief oral sessions**

**STATE OF THE ART 1**

**Organ preservation and enhancements**

The creators view

2017: The limitation of available organs and changing demographics are challenges hindering a more rapid growth in organ transplantation. Clinical efforts and a research focus towards making more organs functioning better and increasing the number of organs available for transplantation are ever more important goals. The race is on: will it be organ reconditioning or creating more organs off the shelf? This session will discuss some of the recent developments that may make organ shortage a thing of the past.

**CREATED BY:** Gabriel Oniscu, Edinburgh, United Kingdom  
Jacques Pirenne, Leuven, Belgium

**09.10 – 10.40**

**09.10 Organ reconditioning should start in the donor**  
Gabriel Oniscu, Edinburgh, United Kingdom

**09.30 Ex-situ organ reconditioning living up to the promise?**  
Peter Friend, Oxford, United Kingdom

**09.50 Origami based tissue engineering**  
Nathaniel Hwang, Seoul, South Korea

**10.10 Choice cuts: growing organs in alternative environments**  
Pablo Juan Ross, Davis, United States
Selecting the right organ for the right patient is an increasing challenge in transplantation. To maintain good outcomes is an increasing challenge in light of both donors and recipients presenting with more unfavorable characteristics. In this session we will focus on global aspects of donation and transplantation and subsequently zoom in on 3 categories of recipients that we commonly encounter in our transplantation clinics. Sergio Leone would name them: The Immunized, The Old and The Diabetic.

CREATED BY: Valentin Cuervas-Mons, Madrid, Spain  
Eelco de Koning, Leiden, The Netherlands

**09.10**  
*World Overview on Transplantation Activities (a report of the Global Observatory on Donation & Transplantation)*  
Beatriz Mahillo, Madrid, Spain

**09.30**  
*The hyper-immunized patient*  
Frans Claas, Leiden, The Netherlands

**09.50**  
*The old patient*  
Uwe Heeman, Munich, Germany

**10.10**  
*The diabetic patient*  
Raja Kandaswamy, Minneapolis, United States

---

Personalised treatment seems the new Holy Grail in medicine. But is it achievable and how far have we advanced in transplantation at this point? In this session, we discuss the experience of large consortia in their search for biomarkers for non-invasive diagnosis of rejection, for guidance on immunosuppression and for patient risk stratification. In addition, we will show that the efforts to discover and validate innovative biomarkers are huge and that the pipeline towards clinical implementation is long. Finally, we look into the mirror but also the crystal ball, evaluating the achievements made to date and the promises for the future.

CREATED BY: Oriol Bestard, Barcelona, Spain  
Maarten Naesens, Leuven, Belgium

**09.10**  
*BIMARGIN - systems biology for non-invasive diagnosis of rejection*  
Wilfried Gwinner, Hannover, Germany

**09.30**  
*BIO-DRIM - marker-assisted immunosuppression individualization*  
Petra Reinke, Berlin, Germany

**09.50**  
*CTOT - biomarkers for transplant risk stratification*  
Peter Heeger, New York, United States

**10.10**  
*The biomarker verdict: prime time or perpetual promise?*  
Dany Anglicheau, Paris, France


11.10 – 12.40  
**BIG BANG 1**  
Technology enhanced medicine

**The creators view**  
We are living in a fast forward moving age, where the convergence of rapidly developing technologies are holding the potential to radically improve and disrupt our day to day life. In this session we invite you to have a glance into the future to see how transplantation will look like years ahead. You will learn a CRISPR way to engineer the human genome, realise that soft robots can support or replace organ function and be impressed by the enormous potential of stem cell biology for generation of human tissues and organs.

**CREATED BY:** Pietro Cippà, Zurich, Switzerland  
Olivier Thaunat, Lyon, France

**CHAIRS:** Pietro Cippà, Zurich, Switzerland  
Olivier Thaunat, Lyon, France

11.10  
**A CRISPR way to engineer the human genome**  
Angelo Lombardo, Milan, Italy

11.40  
**Cardiovascular devices with a difference – light reflecting balloons and soft robots**  
Ellen Roche, Cambridge, United States

12.00  
**KEYNOTE Genetic, epigenetic and cellular approaches to combat disease and aging**  
Juan Carlos Izpisua Belmonte, La Jolla, United States

11.10 – 12.40  
**Best abstract challenge**

11.10 – 12.40  
**Full oral sessions**

13.00 – 14.00  
**Future leaders on stage: life-changing stories**

Are you passionate about your research or clinical area? Show us on a stunning stage!

**The creators view**  
The Young Professionals in Transplantation have launched a competition to future leaders in transplantation to give a seminal presentation at the ESOT congress. Young Professionals have been selected through a call for action on social media. Have a look at the exciting and inspirational presenters that have been selected under 40 years old.

**CREATED BY:** Francesca Tinti, Rome, Italy  
Zeeshan Akhtar, Oxford, United Kingdom

**CHAIRS:** Francesca Tinti, Rome, Italy  
Mohammed Zeeshan Akhtar, Oxford, United Kingdom

13.00  
**A very personal story of success and failure: my journey to social media**  
Omar Taco, Barcelona, Spain

13.20  
**Life-changing event: ‘To improve is to change, to be perfect is to change often.’**  
(Winston Churchill)  
Natalie Vallant, Innsbruck, Austria

13.20  
**Life-changing event: a love worth giving**  
Luke Yates, London, United Kingdom

13.00 – 14.00  
**Elevator Pitch sessions**

13.00 – 14.00  
**Brief oral sessions**
13.00 – 14.30  Launching the EPAT tool for psychosocial assessment of living donors: A workshop from ELPAT

The creators view

The psychosocial assessment of living donor candidates is an integral part of living donor work-up. Yet there are few standardised approaches to ensure the comprehensive and high quality of assessment. There are many international guidelines that suggest ‘what’ but not ‘how’. Developed by the Psychological Care for Living Donors and Recipients working group of ELPAT, the new ELPAT Psychosocial Assessment Tool (EPAT) provides a method for psychosocial evaluation of potential kidney and liver donors. During this workshop we will introduce the EPAT and discuss case studies to illustrate how it can be implemented in clinical practice. This unique workshop is open to all professionals interested in psychosocial screening of living donor candidates. Pre-registration not required!

CHAIRS: Ines Mega, Lisbon, Portugal
Christina Papachristou, Berlin, Germany

13.00  Interactive introduction
Christina Papachristou, Berlin, Germany

13.15  Present the tool
Emma Massey, Rotterdam, The Netherlands

13.30  Case study discussion
Christina Papachristou, Berlin, Germany and Ines Mega, Lisbon, Portugal

14.20  Q&A and future plans

PLENARY SESSION 2

14.05 – 15.35  Trials and tribulations in transplantation

The creators view

Some of the established frameworks and conventional approaches in transplantation are outdated and hinder further progress in the field: endpoints such as BPAR may be less relevant in the modern era while surrogate endpoints e.g. for long term KTx survival are lacking. We herein attempt to shake up your minds and engage in a mind-set that challenges some of the things considered to be ‘true’ or important. Let us rethink the relevance and value of established tools for promotion of progress in clinical science and face the need for change and the challenges that come with it. Welcome to a session that will be rebellious and provocative but also constructive and productive.

CREATED BY: Mark Dahlke, Regensburg, Germany
Alexandre Loupy, Paris, France

CHAIRS: Robert Montgomery, New York, United States
Gabriel Oniscu, Edinburgh, United Kingdom

14.05  What to do when randomized controlled trials stop working
Alexandre Loupy, Paris, France

14.25  I can induce tolerance but nobody wants to believe me
Alberto Sánchez-Fueyo, London, United Kingdom

14.45  Define success in the 2017 transplant world; a path to happiness
Flavio Vincenti, San Francisco, United States

15.05  KEYNOTE Managing change with big data
Value and costs of science and patient care in transplantation: the unwanted truth

The idea of this session is to critically reflect on the value and cost-relationship in transplantation – in reference to science, progress, quality of life, patient behaviour including compliance but also regulatory obligations such as working week regulations. The value of life and costs of suffering as well as the implications of money and patient but also physician behaviour are much debated issues in modern health care. We will touch on strategic thinking in research funding, the implementation from lab inventions to successful enterprises and what can be learned from the free market. In this session, we aim to draw a modern picture of the actual circumstances in healthcare with respect to both the finances of a treatment, but also patient behaviour and their implications on outcome and quality of care. You will experience a different and fresh view on patient care in a rapidly changing environment.

CREATED BY: Stefan Schneeberger, Innsbruck, Austria
Dorry Segev, Baltimore, United States

CHAIRS: Stefan Schneeberger, Innsbruck, Austria
Dorry Segev, Baltimore, United States

16.00 The price for progress
Wim Bens, Maastricht, The Netherlands

16.20 The changing circumstances in health care and their consequences
Scott Halpern, Philadelphia, United States

16.40 The price for patient satisfaction
Sheila Jowsey, Rochester, United States

16.00 – 17.00 Brief oral sessions

16.00 – 18.00 Full oral sessions
16.00 – 18.00  From learners to leaders and Campfire session

16.00  ESOT Education — ESOT Transplant Live & Live Events
Frank Dor, London, United Kingdom
John Forsythe, Edinburgh, United Kingdom

16.10  KEYNOTE  Time is now — modern education
William Plant, Cork, Ireland

16.40  From learners to leaders: introducing the Freudian Walk
O Captain My Captain – how the journey continues
Luca Toti, Rome, Italy

16.50  A growing experience — Part I: keeping the balance
Maruska Nizzi, Milan, Italy

17.00 – 18.00  Transplant Education: the Campfire session
See more information on page 36

17.00  Freudian Walk (3 crews / 3 topics about learning/communicating/sharing)
Crew 1 with captain Wojciech Polak, Rotterdam, The Netherlands
Crew 2 with captain Jacopo Romagnoli, Rome, Italy
Crew 3 with captain Luca Toti, Rome, Italy

17.20  A growing experience — Part II: tips and tricks from senior experts
Maruska Nizzi, Milan, Italy

17.30  Campfire Live (3 crews / 3 campfires)
Crew 1 mentored by captain Wojciech Polak, Rotterdam, The Netherlands
Crew 2 mentored by captain Jacopo Romagnoli, Rome, Italy
Crew 3 mentored by captain Luca Toti, Rome, Italy

17.50  Sharing is caring — a ‘post’ to the leaders
Maruska Nizzi, Milan, Italy
Luca Toti, Rome, Italy
The Devil's Advocate: a moderated controversy in basic science

CHAIRS:
Christine Falk, Hannover, Germany
Thomas Wekerle, Vienna, Austria

Case 1. New insights in the priming of recipient's immune system
Donor dendritic cell-derived exosomes promote allograft-targeting immune response

17.00 Defender: Adrian Morelli, Pittsburgh, United States
17.20 Opponent: Gavin Pettigrew, Cambridge, United Kingdom
17.30 Discussion

Case 2. Impact of microbiota on transplantation outcomes
The composition of the microbiota modulates allograft rejection

17.40 Defender: Maria Luisa Alegre, Chicago, United States
17.50 Opponent: Heinz Zoller, Innsbruck, Austria
18.00 Discussion

17.00 – 18.00
Elevator Pitch sessions

17.00 – 18.00
Brief oral sessions
Tuesday 26 September

**EDUCATIONAL TRACK SESSION 3**

07.30 – 09.00

**Above and below the diaphragm**

**CHAIRS:** Jim Egan, Dublin, Ireland
Annemarie Weissenbacher, Oxford, United Kingdom

07.45

Old and new listing criteria for lung and heart transplantation
John Dark, Newcastle, United Kingdom

08.00

Old and new listing criteria for liver, pancreas and intestinal transplantation
Peter Friend, Oxford, United Kingdom

08.15

How do factors from above the diaphragm impact on the outcome of transplantation of organs below the diaphragm?
Stephan Eschertzhuber, Innsbruck, Austria

08.30

Combined transplanted patients - which organ drives the immunosuppressive regimen?
Nassim Kamar, Toulouse, France

**EDUCATIONAL TRACK SESSION 4**

07.30 – 09.00

**Pathophysiology and endpoints on tolerance**

**CHAIRS:** Cristina Cuturi, Nantes, France
Nina Pilat, Vienna, Austria

07.45

Clinical tolerance studies
Megan Sykes, New York, United States

08.00

Endpoints and biomarkers for clinical tolerance
Birgit Sawitzki, Berlin, Germany

08.15

Macrophages and the induction of tolerance
Jordi Orchando, New York, United States

08.30

T-reg induced allograft tolerance in human
Giovanna Lombardi, London, United Kingdom

08.00 – 09.00

Full oral sessions

08.00 – 09.00

Brief oral sessions
# State of the Art 4

**New concepts in transplant infectious diseases: microbiota and beyond**

**The creators view**

New tools have allowed an unprecedented genetic insight into the composition of our microbiota and our virome. First, we explore the role of the virome and microbiota as it relates to transplantation including potential clinical applications. We aim to elaborate on the impact in transplantation on an individual and epidemiological level. The immunomodulatory role of viruses in transplantation are often mentioned – but does this concept hold up? A critical appraisal of the concept of the indirect effects of viruses is presented. The new anti-HCV drugs have made eradication of HCV in virtually all patients a realistic goal, but how important is a complete control of viral replication in the context of HCV and other viruses?

**Created by:** Maria Luisa Alegre, Chicago, United States  
Marina Berenguer, Valencia, Spain

**Chair:** Maria Luisa Alegre, Chicago, United States  
Marina Berenguer, Valencia, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09.10  | Transkingdom interplay - the complex interactive world of the microbiome  
Dave Wang, St. Louis, United States |
| 09.30  | Knowledge and clinical applications of microbiota in transplantation  
Frederick Bushman, Philadelphia, United States |
| 09.50  | Viruses and the recipient immune response: relevant crosstalk in transplantation  
Oriol Manuel, Lausanne, Switzerland |
| 10.10  | The impact of HCV treatment on liver transplantation  
Audrey Coilly, Paris, France |

# State of the Art 5

**Cell therapy in clinical trials**

**The creators view**

Cell therapy may be a suitable adjunct to conventional immunosuppression. Despite a major enthusiasm, however, major issues emerged in the first clinical applications. The question now is: how can technical and regulatory hurdles be overcome within a reasonable time frame? Will cell therapy ever be commercially interesting and will its implementation enhance solid organ transplantation? Experts share their experience and explain what we might expect from cell therapy tomorrow and in 10 years.

**Created by:** Pietro Cippà, Zurich, Switzerland  
Marc Dahlke, Regensburg, Germany

**Chairs:** Marc Dahlke, Regensburg, Germany  
Thomas Wekerle, Vienna, Austria

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09.10  | Technical and regulatory issues. From the idea to the clinical application  
Marlies Reinders, Leiden, The Netherlands |
| 09.30  | Sharing clinical experience. What can we learn from hematologists?  
Francesco Dazzi, London, United Kingdom |
| 09.50  | Translational studies. Why do we need cell therapy if we cannot avoid severe immunosuppression?  
Suzanne T. Ilstad, Louisville, United States |
| 10.10  | The future: clinical applications of stem cells in the context of transplantation vs. regeneration?  
Martin Johannes Hoogduijn, Rotterdam, The Netherlands |
**STATE OF THE ART 6**

**One for all or all for one: moving away from protocolized medicine**

The ultimate goal of transplantation is long-term survival with a well-functioning graft. Operationalization of post-transplant care with protocols based on evidence from clinical trials has had an important impact on the overall outcome in transplantation. It is increasingly recognized though, that the ‘one size fits all’ approach does not always optimally reflect the patient’s individual need. Hence, the concept of personalized medicine is on everyone’s lips. This session aims to confront the reality by focusing on four important topics in the field.

**CREATED BY:** Georg Böhmg, Vienna, Austria
Nicolas Müller, Zurich, Switzerland

**CHAIRS:** Georg Böhmg, Vienna, Austria
Nicolas Müller, Zurich, Switzerland

09.10
**Is transplantation ready for systems medicine?**
Rainer Oberbauer, Vienna, Austria

09.30
**Individualized antimicrobial prophylaxis**
Jay Alan Fishman, Boston, United States

09.50
**Phenotypic diversity of rejection and allograft dysfunction**
Phil Halloran, Edmonton, Canada

10.10
**Tailored immunosuppression**
Christian Hugo, Dresden, Germany

**BIG BANG 3**

**Innovation in immunomedication: the modern Prometheus**

Following the steps of Dr Frankenstein, scientists have begun stitching together disparate biological pieces to create new therapeutic opportunities and, far from sci-fi fantasies, these therapeutic innovations have already shown promising results in the field of cancer therapy. Their potential to revolutionise solid organ transplantation will be scrutinised during this Big Bang session.

**CREATED BY:** Josep Maria Grinyó, Barcelona, Spain
Olivier Thaunat, Lyon, France

**CHAIRS:** Fadi Lakkis, Pittsburgh, United States
Julien Zuber, Paris, France

11.10
**Deciphering and targeting protein-protein interactions: a new challenge in biomedicine**
Juan Fernández Recio, Barcelona, Spain

11.30
**The potential of bispecific antibodies**
Jeffrey S. Miller, Minneapolis, United States

11.50
**Alloantigen-specific regulatory T-cells generated with a chimeric antigen receptor**
Megan Levings, Vancouver, Canada

12.10
**Systems biology applications for prognostication and therapeutics**
Patrick Aloy, Barcelona, Spain
Asia leading the way
(Joint session with the Asian Society for Transplantation)
This session was jointly organized with the Asian Society for Transplantation and aims to highlight some of the significant advancements in transplantation achieved in the recent past. We are proud to bring to your attention programmes and topics from our partners in Asia.

CHAIRS: Jan Lerut, Brussels, Belgium
Dennis Serrano, Quezon City, Philippines

11.20  Tissue repair and its relevance to transplantation
Nathaniel S. Hwang, Seoul, South Korea

11.40  Challenges in increasing organ donation in Asia
Romina Danguilan, Manila, Philippines

12.00  ABO incompatible kidney transplantation: future directions
Shiro Takahara, Osaka, Japan

12.20  State of the art of living donor liver transplantation
Chao Long Chen, Kaohsiung City, Taiwan

11.10 – 12.40  Elevator Pitch sessions
11.10 – 12.40  Full oral sessions
Surrogate Endpoints International Workshop

Drug development in transplantation has diminished due to the lack of fitting endpoints, the long timespan between transplantation and graft failure and the low rates of early rejection. At the same time, we find patients suffering from long-term graft loss. Hence it is paramount to establish new principles to allow development of novel therapeutics to treat and prevent this from happening. One of the main objectives in our drive to address this is to identify and validate surrogate markers for long-term graft outcome and identify novel endpoints for trials and drug development. The field of transplantation is facing one of the greatest challenges hindering further advancement of this field and all individuals and institutions involved in this field need to work together to prevail. In this interactive session, we will discuss the need for new endpoints in the field of transplantation, the potential and problems with histology, the applicability of donor-specific antibodies, and the promise of combined calculated markers as surrogate endpoints. We will discuss the progress that has and can be achieved by transplant societies and health authorities. The session will focus on kidney transplantation, although the methodology and conclusions are likely valid also for other organs.

CREATED BY: Maarten Naesens, Leuven, Belgium
Stefan Schneeberger, Innsbruck, Austria

CHAIRS: Maarten Naesens, Leuven, Belgium
Stefan Schneeberger, Innsbruck, Austria

13.00
Why do we need new endpoints
Mark Stegall, Rochester, United States

13.10
The potential of combined calculated surrogate endpoints
Alexandre Loupy, Paris, France

13.22
The difficult but important place of histology as endpoint
Maarten Naesens, Leuven, Belgium

13.34
DSAs as surrogate endpoint for drug development
Peter Nickerson, Winnipeg, Canada

13.46
Panel discussion

13.00 – 14.00
Brief oral sessions

Innovation under pressure: transplant patient care in 2020

Health care is undergoing a fundamental change. While new fields in medicine are emerging and short-term results are satisfactory, long-term care of patients after transplantation is more complex and challenging than ever. While novel technologies may help to effectively monitor patients after transplantation, novel structures and business models are warranted to ensure optimal patient care and advancement of the field.

CREATED BY: Marina Berenguer, Valencia, Spain
Antonio Roman, Barcelona, Spain

CHAIRS: John Forsythe, Edinburgh, United Kingdom
Christophe Legendre, Paris, France

14.05
Prospects and pushbacks in hand face uterus abdominal wall penile transplant and others
Wei-Ping Andrew Lee, Baltimore, United States

14.25
Beyond survival: quality of life after transplantation
Lianne Singer, Toronto, Canada

14.45
New tech for new patients: digital communication and self-monitoring
Giral Magali, Nantes, France

15.05
KEYNOTE New models for patient care: wish for what you care for
Marcel Levi, London, United Kingdom
In this session, we discuss the changing demographics of donors and recipients and its impact on transplantation in reference to organ quality, ischemia-reperfusion injury and immunosenescence. In addition, the biology of ageing and the concept of accelerated ageing after transplantation with its implications on the fate of the graft and the patient are being addressed.

As a consequence of the changing demographics, transplant allocation organisations are implementing age-matching in their allocation procedures. The benefits and the potential drawbacks of these important changes are discussed. Finally, we will evaluate innovative ways to halt or slow down these ageing processes, and discover the clues to immortality.

**CREATED BY:**

Maarten Naesens, Leuven, Belgium
Olivier Thaunat, Lyon, France

**CHAIRS:**

Maarten Naesens, Leuven, Belgium
Olivier Thaunat, Lyon, France

**16.00**

**Older graft, older recipients, young ideas**

*Stefan Tullius, Boston, United States*

**16.20**

**Accelerated ageing after transplantation**

*Peter Stenvinkel, Stockholm, Sweden*

**16.40**

**Halting aging: the science of rejuvenation**

*Brian Kennedy, Novato, United States*

---

The format of this session will be the presentation of the article by the author followed by a critical discussion by the ‘opponent’ and a rebuttal and general discussion with the audience. It will be a highly interactive session.

**CREATED BY:**

Josep Maria Grinyó, Barcelona, Spain
Rainer Oberbauer, Vienna, Austria

**CHAIRS:**

Josep Maria Grinyó, Barcelona, Spain
Rainer Oberbauer, Vienna, Austria

**Case 1. Ethical debate**

**Allocating organs to cognitively impaired patients**

*Scott D. Halpern, M.D., Ph.D., and David Goldberg, M.D., M.S.C.E.  N Engl J Med 2017*

**16.00**

Defender: Scott Halpern, United States

**16.20**

Opponent: Michael Bos, Leiden, The Netherlands

**16.30**

Discussion

**Case 2. Expensive but useless?**

**Clinical value of C1q assay in antibody-mediated rejection**

*Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival*


**16.40**

Defender: Peter Nickerson, Winnipeg, Canada

**16.50**

Opponent: Denis Glotz, Paris, France

**16.30**

Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00 – 17.00</td>
<td>Brief oral sessions</td>
</tr>
<tr>
<td>17.05 – 18.35</td>
<td>Full oral sessions</td>
</tr>
<tr>
<td>17.05 – 18.35</td>
<td>ESOT General Assembly</td>
</tr>
<tr>
<td>18.40 – 19.35</td>
<td>Elevator Pitch sessions</td>
</tr>
<tr>
<td>18.40 – 19.35</td>
<td>Brief oral sessions</td>
</tr>
<tr>
<td>19.35 – 20.20</td>
<td>Rising Stars Networking Cocktail</td>
</tr>
</tbody>
</table>
Wednesday 27 September

EDUCATIONAL TRACK SESSION 5

07.30 – 09.00
Infection diseases
CHAIRS: Alain Le Moine, Brussels, Belgium
Frederike Bemelman, Amsterdam, The Netherlands

07.45
Prophylaxis of infections in solid organ transplantation (including donor derived infections)
Jay Alan Fishman, Boston, United States

08.00
Infectious diseases in the central nervous system of solid organ transplant patients
Peter Portegies, Amsterdam, The Netherlands

08.15
Fungal and yeast infections in SOT patients
José María Aguado, Madrid, Spain

08.30
Impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation
Oriol Manuel, Lausanne, Switzerland

EDUCATIONAL TRACK SESSION 6

07.30 – 09.00
The allograft phenotype and its clinical implications
CHAIRS: Lorna Marson, Edinburgh, United Kingdom
Marlies Reinders, Leiden, The Netherlands

07.45
Allo-immune responses: what a clinician should know
Frans Claas, Leiden, The Netherlands

08.00
Rejection phenotypes across organs: revisiting the basics
Chris Bellamy, Edinburgh, United Kingdom

08.15
How to integrate complex histological phenotypes in routine clinical decision making?
Daniel Serón, Barcelona, Spain

08.30
Time to make computer-assisted instead of eminence-based decisions?
Alexandre Loupy, Paris, France

08.00 – 09.00
Full oral sessions

08.00 – 09.00
Brief oral sessions
STATE OF THE ART 7
09.10 – 10.40
Donor management – can we further extend the potential donor pool?

The creators view
The prerequisite for successful transplantation is the availability of organs. At the same time, selecting suitable organs for transplantation is critical in order to guarantee optimal short- and long-term outcomes. During the last years, we have experienced an increasing interest in strategies to optimize donor management, especially since liberalization of donor criteria has been introduced within the field. In this session, we want to address the idea of further extending the potential donor pool. The focus will be recent innovative approaches and potential risk factors, that might limit further expansion. In this session we want to engage all professionals involved in this topic, including anaesthesiologists, intensivists, nurses, coordinators and transplant physicians in a lively exchange and discussion.

CREATED BY: Arne Neyrinck, Leuven, Belgium
Jacques Pirenne, Leuven, Belgium

CHAIR: Arne Neyrinck, Leuven, Belgium
Beatriz Dominguez-Gil, Madrid, Spain

09.10
How controlled is my DCD?
Sophie Van Cromphaut, Leuven, Belgium

09.30
Should I perfuse my donor?
Simon Messer, Cambridge, United Kingdom

09.50
Tribulation in designing donor intervention studies
Claus Niemann, San Francisco, United States

10.10
How clean is my donor?
Margaret Hannan, Dublin, Ireland

STATE OF THE ART 8
09.10 – 10.40
Pushing the boundaries in living donation

The creators view
Live donation has become routine practice in many countries. The expansion of the acceptance criteria for live kidney donors is now challenged by emerging evidence for an increased relative risk for the development of renal failure on the long run. In this context, it is even more important how transplant professionals provide an individual risk assessments for potential donors. But how can we ensure that donors understand the potential risks? Do we have a good screening tool to assess potential psychological risks for live donors? Can we step away from standardized surgical approaches for live donor nephrectomy and adopt a tailor made approach? Should living donor liver transplantation be advocated to replace deceased donor liver Tx? This session focuses on the balance between pushing the limits in the context of potential short and long-term complications in this field.

CREATED BY: Frank Dor, London, United Kingdom
Gabriel Oniscu, Edinburgh, United Kingdom

CHAIR: Barış Akin, Ankara, Turkey
Lisa Burnapp, Watford, United Kingdom

09.10
To be or not to be a donor – how can we make sure potential donors understand the risks?
Aisling Courtney, Belfast, Ireland

09.30
Psychosocial evaluation of live donors - the need for a tool to determine the psychological risk
Fabienne Dobbels, Leuven, Belgium

09.50
Tailor made live donor nephrectomy: a conversation between two surgeons
Frank Dor, London, United Kingdom and Gabriel Oniscu, Edinburgh, United Kingdom

10.10
Should live liver donor transplantation be advocated to substitute deceased donor liver Tx?
Yaman Tokat, Istanbul, Turkey
State of the Art 9

Cellular interaction in rejection

Transplant rejection involves a coordinated attack of the graft by the recipient’s innate and the adaptive immune systems. Although direct visualization of this complex cellular interplay as made possible by recent technological progresses has greatly improved our understanding of rejection pathophysiology, it has also led to unexpected observations. Indeed, like in other chronic inflammatory conditions, organized lymphoid tissue develop in allografts. This session will provide an update on cellular interactions in rejection and will discuss whether intragraft tertiary lymphoid organs contribute to graft rejection and/or tolerance.

**The creators view**

CREATED BY: Lorna Marson, Edinburgh, United Kingdom
Olivier Thaunat, Lyon, France

**CHAIRS:** Carla Baan, Rotterdam, The Netherlands
Lorna Marson, Edinburgh, United Kingdom

09.10

**Visualizing cell trafficking and the underlying allosensitization by two-photon microscopy**
Adrian Morelli, Pittsburgh, United States

09.30

**T cell migration to vascularized transplants**
Fadi Lakkis, Pittsburgh, United States

09.50

**Lymphoid neogenesis: a tribute to the travelers**
Nancy Ruddle, New Haven, United States

10.10

**Intragraft tertiary lymphoid organs: friends and foes**
Olivier Thaunat, Lyon, France

Plenary Session 4

Leadership in transplantation and Presidential Session

Leadership is a key element in our professional lives, yet the attention to professionalism in this area has not received much attention. Much of the potential in our field could be mobilized by enhancing the understanding of the principles in modern leadership. In this final plenary session, you will hear from individuals within and outside of transplantation about their experience and their own views on leadership.

As per the tradition of the ESOT conference, you will also be presented with a summary of the most exciting innovations that have been discussed during the congress in this session.

**The creators view**

CREATED BY: Lorna Marson, Edinburgh, United Kingdom
Stefan Schneeberger, Innsbruck, Austria

**CHAIRS:** Thierry Berney, Geneva, Switzerland  ESOT CURRENT PRESIDENT
Stefan Schneeberger, Innsbruck, Austria  ESOT PRESIDENT ELECT

11.00

**Clinical: What’s hot!**
Dennis Hesselink, Rotterdam, The Netherlands

11.20

**Basic Science: What’s hot!**
Oriol Bestard, Barcelona, Spain

11.40

**Leadership in transplantation!**
Dorry Segev, Baltimore, United States and Robert Montgomery, New York, United States

12.10

**KEYNOTE Leadership**
Javier Solana, Madrid, Spain

12.30

**Presidential address**
Stefan Schneeberger, Innsbruck, Austria
The Education Committee is dedicated to:

- Promoting the overall educational philosophy and programs of ESOT.
- Organising and supporting the advanced courses which are part of the formal ESOT education pathway.
- Collaborating with the ECs of Transplant Societies across Europe and beyond to promote transplant education in a mutually beneficial way.
- Providing quality control for the UEMS-ESOT Exams in Transplantation, Surgery, Medicine, Coordination and Immunology.
ESOT 2017 Congress registration fees

ESOT 2017 will be a paperless congress. Printed matter will be fully replaced by a multi-feature app to maximise participants’ engagement and connectivity.

<table>
<thead>
<tr>
<th>TYPE OF REGISTRATION</th>
<th>EARLY (until 13 June)</th>
<th>REGULAR (until 31 August)</th>
<th>LATE (from 1 September)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESOT Member</td>
<td>600€</td>
<td>700€</td>
<td>730€</td>
</tr>
<tr>
<td>Non-member</td>
<td>850€</td>
<td>950€</td>
<td>980€</td>
</tr>
<tr>
<td>Easy ESOT:incl. reg to the Congress and ESOT membership fee</td>
<td>700€</td>
<td>800€</td>
<td>830€</td>
</tr>
<tr>
<td>Individuals qualifying for a reduced fee, members only*</td>
<td>360€</td>
<td>410€</td>
<td>440€</td>
</tr>
</tbody>
</table>

*Reduced fee* (applies only to ESOT members)
Trainees, nurses, transplant co-ordinators, allied health professional / participants from low/middle income countries¹, local hospital staff members.

¹According to World Bank list: http://data.worldbank.org/country

Delegate registration fee includes:
- Admission to all scientific sessions
- Access to the exhibition
- Participant’s kit with congress material
- Provision of the required device for use throughout the duration of the congress
- Admission to all Specialty Update Symposia
- Access to the delegate lounges
- Admission to poster opening and networking reception
- Refreshment breaks

Fees are inclusive of VAT at the prevailing rate (21% in March 2017)

60€ discount from the relevant congress fee for participants with their own device!
ESOT Awards 2017

**BAC – Best Abstract Challenge**

Supported by [Biotest](#)

Each award amounts to 2.500 Euro.

The challenge made up of 10 finalists, will take place during the BAC session on Monday 25 September from 11.10 to 12.40.

A selection of 10 outstanding contributions will be made by the ESOT2017 Scientific Program Committee from all submitted abstracts and based on the overall referees’ score, the audience will then vote to select 6 winners.

The award winners will be celebrated during the presentation session.

**YIA – Young Investigator Awards**

Supported by [Roche](#)

Each award amounts to 1.500 Euro.

10 awards will be given to young clinicians or scientists (under 40 years of age in 2017), who have submitted abstracts to #ESOT2017 #BigBangBarcelona.

Submitters are requested to select the ‘Young Investigator’s Award’ option in the abstract application process.

The awards are selected by the Scientific Programme Committee of the ESOT2017 Congress, and advised by email at the same time as the abstract notification. The award winners will be celebrated during the presentation session.

**StrongerTogether Award**

Supported by European National Transplant Societies

The award amounts to 2.500 Euro.*

The award will be given to the largest group of abstracts (minimum 5) submitted by a single transplant centre/unit/institution/hospital.*

The award is selected by the Scientific Programme Committee of the ESOT2017 Congress and advised by email at the same time as the abstract notification.

The award winner will be celebrated on Tuesday 26 September from 19.30 to 20.15 in the Rising Stars Lounge.

* The award will be given to a single centre/unit/institution/hospital – not to individuals.

**StrongerTogetherPro Award**

The award amounts to 5.000 Euro.*

This award will be given to the group of abstracts (minimum 5) submitted by a single transplant centre/unit/institution/hospital* with the best average score amongst all group of abstracts submitted by single centres/units/institutions/hospitals.

The award is selected by the Scientific Programme Committee of the ESOT2017 Congress and advised by email at the same time of the abstract notification.

The award winner will be celebrated on Tuesday 26 September from 19.30 to 20.15 in the Rising Stars Lounge.

* The award will be given to a single centre/unit/institution/hospital – not to individuals.
ESOT Awards 2017

BE – Best #ESOTtrustedPartner Award

Supported by Castellas

The award amounts to 500 Euro.

The #ESOTtrustedPartner awards will be given to the most active #ESOTtrustedPartner in the time period from 31/01/2017 until the opening event of the congress. A special tool will keep track of social media posts (via Twitter/LinkedIn/Instagram/Facebook).

The award winner will be celebrated on Tuesday 26 September during the coffee break at 15:35 in the ESOT Village.

* Winners will be notified by 24/09/2017

#ESOTtrustedPartner members have a dedicated group on LinkedIn.

The Group: ESOT members are invited to become Trusted Partners to boost communication and information about all activities #PoweredByESOT, with a special focus on the International Transplant Congress which is held every two years.

The Goal: To build on the communication around #ESOT2017 and other educational opportunities #PoweredByESOT, by acting/reacting in this group, echoing in your preferred platforms and sharing the promotional messages prepared for our events.

The official hashtags (# mainly for Twitter, Facebook and Instagram) are:

#ESOT2017 and/or #BigBangBarcelona (Congress)
#PoweredByESOT (any ESOT educational opportunities).

EuroLiver Award

Supported by Euroliver

Each award amounts to 1.000 Euro.

The Euroliver Foundation was set up in 1992 by the late Mr Herman Tob and Prof. Jean-Bernard Otte of the University Hospital St-Luc in Brussels, Belgium in order to support research projects in the field of liver transplantation and organ donation, and also to improve the psychosocial support of both future liver recipients and liver transplant patients.

More info on the past editions available here: euroliver.org/content/euroliver-foundation-awards

2 awards are assigned to young researchers who have made a valuable contribution in relation to these topics.

Awards are assigned by the Scientific Programme Committee and announced before the congress.

The award winners will be celebrated during the presentation Session.

ESOT has always been committed to education and research. At ESOT 2017 Conference we will be pleased to recognize the excellence of professionals who show outstanding results.

YIA and TrustedPartners awardees will be required to be ESOT members for 2017.
Special thanks to our partners and supporters!

As a sponsor or exhibitor ESOT 2017 offers you a strong platform to:

- Meet your target group with the potential to gain 4000 strong business leads.
- Be recognized as the ultimate solution provider.
- To be seen as a principal supporter.
- Have the fundamental face-to-face conversation.
- Promote new products.
- Be associated with the latest medical research in the field of organ transplantation.
ESOT 2017 Congress Supporters

**SILVER**
- Neovii
- Novartis
- Organ Recovery Systems
- Sandoz (a Novartis Division)
- Sanofi
- Genzyme
- Biotest

**BRONZE**
- Immucor

**EXHIBITORS**
- Fresenius Medical Care
- Hansa Medical
- IGL
- Wiley
- Dr. F. Köhler Chemie
- Lophius Biosciences
- Macopharma
- Salf
- WisePress.com (your medical bookshop)
- E3 Cortex
- Oxford Immunotec
- Organ Assist
- Qiagen
- Ecolab
- Immudex
- Glycorex Transplantation
- Organox
- IvTransplant
- Xvivo Perfusion
- Coloplast

**NON-PROFIT ORGANISATIONS**
- The Transplantation Society
- Başkent University
- Maastricht UMC+
- ITransplant
- Biomargin
- International Transplant Network
ESOT2017 Corporate Symposia

**Sunday 24 September**

13.00 – 14.30  Corporate Parallel Symposium
   ![Biotest](image)

13.00 – 14.30  Corporate Parallel Workshops
   ![IMMUCOR](image)

**Monday 25 September**

13.00 – 14.00  Corporate Parallel Lunch Symposia
   ![Chiesi](image)  ![ONE LAMBDA](image)  ![SANDOZ](image)

18.00 – 19.30  Corporate Plenary Symposium
   ![Astellas TRANSPLANT](image)

**Tuesday 26 September**

13.00 – 14.00  Corporate Parallel Lunch Symposia
   ![Novartis](image)

13.00 – 14.00  Corporate Parallel Lunch Workshop

17.00 – 18.30  Corporate Parallel Symposia
   ![MEI](image)  ![PIM](image)
Ecosystem

ESOT is committed to maximising participant engagement and connectivity, as well as event sustainability. Once again, the ESOT Congress will be fully paperless. At ESOT2017, a dedicated app with its fully digitalized environment will make your meeting experience easier and more enjoyable than ever, facilitating the interaction with your peers and helping you find the content that is most relevant to you.

About the venue

The CCIB is a unique space that came into being with the 2004 Universal Forum of Cultures, with the goal of welcoming congresses, conventions, exhibitions and official events on the highest level from around the globe.

Its innovative features, unmistakable architecture, cutting-edge technology and sustainable event management, combined with its superb location facing the Mediterranean, make the CCIB an outstanding venue.

CCIB Centre de Convencions Internacional de Barcelona
Pl. de Willy Brandt 11-14, 08019 Barcelona, Spain
www.ccib.es

Hotel accommodation

Barceló Congresos has been appointed as the Official Housing Bureau of ESOT 2017 Congress and is offering you the opportunity to book accommodation in a selection of Barcelona’s best hotels at preferential negotiated rates for the attendees. A wide range of hotel categories will be available in the CCIB area, venue of the congress, some walking distance and others well connected by public transport. Hotel reservations will be made available at a later stage at: www.esot.org
**Important dates:**

- **Abstract submission closes**  12 March 2017
- **Notifications dispatched on/from**  31 May 2017
- **Early registration deadline**  13 June 2017
- **Late breaking abstract submission opens**  2 June 2017
- **Late breaking abstract submission closes**  30 June 2017
- **Late breaking abstract submission notifications despatched on/from**  10 July 2017

A future powered by experience

---

**neovii**

is proud to be a supporter of the ESOT 2017 Barcelona Congress

Come and visit our booth on level P0 in the congress centre

Neovii is committed to developing novel therapies in transplant and haematology/oncology
Come and experience it!

24 - 27 September 2017 · Barcelona · Spain
CONTACTS

ESOT 2017 Congress Secretariat

ESOT OFFICE
Riviera dei Mugnai 8/24
35137 Padua · Italy
Tel: +39 049 859 76 52
Fax: +39 049 210 63 06
esot2017@esot.org

Congress Administrative Secretariat

BARCELÓ CONGRESOS
Pl. Europa 17-19, 1st floor
08908 L'Hospitalet de Llobregat
Barcelona · Spain
Tel: +34 938 823 878
Fax: +34 971 593 811
esot2017@barcelocongresos.com

Transplantation
BigBangBarcelona

visit esot.org